Looking for a replacement for Mounjaro? Here is what the evidence says

Step 1: Understand why you need a replacement — the reason shapes the answer

The most common misconception here is that switching weight-loss injections is like swapping one brand of paracetamol for another. It is not. Each medicine acts differently, titrates differently, and suits different people differently. That said, there are clear, sensible steps to work through.

First, pin down the actual reason. Mounjaro may have become unavailable at your current dose, which has happened at certain strengths at various points since its UK launch. Or you may have experienced side effects that haven't settled. Or a prescriber has flagged a clinical reason it is no longer appropriate. Each situation points toward a different next step — and a prescriber who knows your record is the person best placed to map them out. Our eligibility guidance for Mounjaro covers the licensed criteria in detail if you want to revisit what qualified you in the first place.

If the issue is simply a supply gap at one dose, waiting or using a neighbouring strength under prescriber guidance is often the cleaner solution than switching entirely. If the issue is tolerability, the alternative medicines have overlapping but not identical side-effect profiles, and your experience on tirzepatide gives a prescriber useful information. Getting the reason straight is genuinely step one.

Step 2: Know the licensed alternatives and what the evidence actually says

Wegovy injection (semaglutide 2.4mg weekly, rising to 7.2mg following the MHRA's April 2026 approval of the higher-dose pen) is the closest like-for-like replacement in structure: once-weekly subcutaneous injection, similar eligibility, similar lifestyle requirements. Where they differ is mechanism. Mounjaro activates two receptors (GIP and GLP-1) while Wegovy targets GLP-1 alone.

In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. The gap narrows at semaglutide's 7.2mg maintenance dose, which reported around 20.7% average weight loss in trials. That is still broadly lower than tirzepatide's SURMOUNT-1 results at 15mg (around 20–21% average), but the difference is smaller than older comparisons suggested.

For patients who prefer not to inject at all, Wegovy tablets offer a genuinely different route. The MHRA approved oral semaglutide for weight management on 11 June 2026, making the UK the first country in Europe to do so. The once-daily tablet (taken on an empty stomach before food or drink, starting at 1.5mg and escalating to a 25mg maintenance dose) produced around 13.6% average weight loss in the OASIS 4 phase-3 trial. Among participants who stayed fully adherent, the figure rose to around 17%. It is a lower average than the injectable options at maximum dose, but for someone with needle anxiety or a lifestyle that makes weekly injections difficult, the practicality argument is real. You can read more about tirzepatide's full profile if you want a baseline to compare from.

Step 3: Factor in eligibility, cost and what the NHS covers

Both Mounjaro and Wegovy share broadly the same private eligibility floor: adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as type 2 diabetes, high blood pressure or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Oral semaglutide holds the same licensed criteria.

On the NHS, access is more constrained. NICE's appraisal of tirzepatide (TA1026) set strict phased rollout criteria; Wegovy (TA875) requires specialist weight management services and carries a two-year maximum. If you do not meet NHS thresholds or do not want to wait, a regulated private pharmacy is the alternative route, and cost is a reasonable consideration when comparing options.

Our Mounjaro pricing page explains what the current market looks like, and for anyone weighing up whether to continue tirzepatide versus move to semaglutide, the difference in private monthly cost is worth factoring in during your prescriber conversation. Cheaper does not automatically mean better suited, and for any prescription medicine, the clinical fit matters more than the price. If payment flexibility is a concern, payment plan options for Mounjaro are worth exploring separately.

Step 4: What a clinical review should cover before any switch

A prescriber switching you between weight-loss medicines should ask: how much weight did you lose and over how long; what side effects did you experience and when; any changes to your health conditions since you started; and what your current dose was. That picture shapes whether you start a replacement at the lowest titration or whether a different entry point is clinically appropriate.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally. Transfer patients provide evidence of their current treatment, and any dose change, including a switch to a new medicine, goes through the same clinical review before anything is dispatched. If you are weighing up your options, our guide to finding the best place to get Mounjaro sets out what we offer and how each medicine compares in practice. When you are ready to speak to a prescriber, and you want practical guidance on technique as well as sourcing, our advice on where to give yourself the Mounjaro shot covers that alongside how to check your eligibility through a free consultation, there is no obligation and no fee to find out where you stand.